Patient Name:	N	/IRN: _		Study Identifier:								
		Baseline Scan Date:										
New RECIST V 1.1  Measurable Lesions Longest diameter ≥ 10 mm Lymph nodes ≥ 15 mm in short axis  Lymph nodes ≥ 15 mm in short axis  Target Lesions All measurable les maximum – two le and five lesions in representative of a				Non- Target Lesions s up to a ns per organ al  Non- Target Lesions All lesions or sites of disease not identified lesions should be identified & followed as 'absent', or 'unequivocal progression'						ved as 'pre n' > 10 mm	esent',	
** All lesions recorded as target lesions at baseline should have their actual measurements recorded at each subsequent evaluation if possible, even when very small.												
Date of Evaluation		mm/dd/yyyy		mm/dd/yyyy		mm/dd/yyyy		mm/dd/yyyy		mm/dd/yyyy		
Target Lesions *Instructions: Enter longest dimension (LD) in millimeters (mm)  Lymph nodes – enter short axis measurement in millimeters (mm)												
		L;							illimeters (mm)			
Description	Imaging Modality	Slice	*	Slice	*	Slice	*	Slice	*	Slice	*	
1.												
2.												
3.												
4.												
5.												
Total / % change from screening/nadir		mm%								mm%		
Date used for Comparison		//		//		//						
		ns: Enter <b>P</b> (Pre		esent), A (abser		nt), I (increased		), <b>D</b> (decreased		), <b>S</b> (stable)		
Description	Imaging Modality	Slice	*	Slice	*	Slice	*	Slice	*	Slice	*	
1.												
2.												
3.												
4.												
5.												
New Lesions *Instructions: Enter <u>longest dimension (LD)</u> in millimeters (mm)  Lymph Nodes – enter short axis measurement in millimeters (mm)												
	Imaging								`	<u> </u>		
Description	Modality	Slice	*	Slice	*	Slice	*	Slice	*	Slice	*	
Comments:												
Response: CR = Complete Response; PR = Partial Response SD = Stable Disease; PD = Progressive Disease		CR □ PR □ SD □ PD □		CR		CR □ PR □ SD □ PD □		CR   PR   SD   PD		CR □ PR □ SD □ PD □		
Reviewed By Investigator (sign & date)									_			